TTNP Stock Overview
A pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Titan Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.00 |
| 52 Week High | US$14.80 |
| 52 Week Low | US$3.57 |
| Beta | 1.08 |
| 11 Month Change | -24.44% |
| 3 Month Change | -29.98% |
| 1 Year Change | -53.43% |
| 33 Year Change | -88.22% |
| 5 Year Change | -96.03% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?
Jul 10
Titan Pharma regains Nasdaq listing compliance
Dec 16Titan Pharmaceuticals announces 1-for-30 reverse stock split
Nov 30Titan Pharmaceuticals EPS misses by $0.01, beats on revenue
Nov 16Titan Pharma closes debt settlement and JT-09 acquisition
Nov 02Titan Pharma to raise $8M in stock offering
Oct 28Shareholder Returns
| TTNP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.8% | -3.7% | -1.6% |
| 1Y | -53.4% | 17.2% | 30.8% |
Return vs Industry: TTNP underperformed the US Pharmaceuticals industry which returned 17.2% over the past year.
Return vs Market: TTNP underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| TTNP volatility | |
|---|---|
| TTNP Average Weekly Movement | 30.5% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TTNP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TTNP's weekly volatility has increased from 20% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 4 | n/a | www.titanpharm.com |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Titan Pharmaceuticals, Inc. Fundamentals Summary
| TTNP fundamental statistics | |
|---|---|
| Market cap | US$3.66m |
| Earnings (TTM) | -US$5.46m |
| Revenue (TTM) | US$3.00k |
1,220x
P/S Ratio-0.7x
P/E RatioIs TTNP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTNP income statement (TTM) | |
|---|---|
| Revenue | US$3.00k |
| Cost of Revenue | US$910.00k |
| Gross Profit | -US$907.00k |
| Other Expenses | US$4.55m |
| Earnings | -US$5.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.97 |
| Gross Margin | -30,233.33% |
| Net Profit Margin | -182,033.33% |
| Debt/Equity Ratio | 0% |
How did TTNP perform over the long term?
See historical performance and comparison